Fortress Biotech, Inc. (FBIO)
2.01
-0.10
(-4.74%)
USD |
NASDAQ |
Oct 13, 13:17
Fortress Biotech Free Cash Flow (Quarterly) : -59.36M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -59.36M |
| March 31, 2026 | 203.85M |
| December 31, 2025 | -18.10M |
| September 30, 2025 | -6.11M |
| June 30, 2025 | -27.56M |
| March 31, 2025 | -19.56M |
| December 31, 2024 | 23.09M |
| September 30, 2024 | -71.06M |
| June 30, 2024 | -21.84M |
| March 31, 2024 | -25.39M |
| December 31, 2023 | -35.00M |
| September 30, 2023 | -17.78M |
| June 30, 2023 | -40.32M |
| March 31, 2023 | -43.22M |
| December 31, 2022 | -48.24M |
| September 30, 2022 | -64.41M |
| June 30, 2022 | -41.73M |
| March 31, 2022 | -48.20M |
| December 31, 2021 | -40.11M |
| September 30, 2021 | -29.74M |
| June 30, 2021 | -40.89M |
| March 31, 2021 | -22.15M |
| December 31, 2020 | -22.05M |
| September 30, 2020 | -26.65M |
| June 30, 2020 | -18.48M |
| Date | Value |
|---|---|
| March 31, 2020 | -23.67M |
| December 31, 2019 | -29.74M |
| September 30, 2019 | -20.01M |
| June 30, 2019 | -28.98M |
| March 31, 2019 | -25.62M |
| September 30, 2018 | -27.89M |
| June 30, 2018 | -27.93M |
| March 31, 2018 | -28.68M |
| December 31, 2017 | -28.07M |
| September 30, 2017 | -27.74M |
| June 30, 2017 | -21.89M |
| March 31, 2017 | -13.55M |
| December 31, 2016 | -19.10M |
| September 30, 2016 | -11.28M |
| June 30, 2016 | -11.60M |
| March 31, 2016 | -14.16M |
| December 31, 2015 | -7.776M |
| September 30, 2015 | -6.582M |
| June 30, 2015 | -7.868M |
| March 31, 2015 | -10.08M |
| December 31, 2014 | -3.527M |
| September 30, 2014 | -2.321M |
| June 30, 2014 | -4.014M |
| March 31, 2014 | -6.074M |
| December 31, 2013 | -6.985M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | -18.05M |
| Kura Oncology, Inc. | -63.20M |
| Spero Therapeutics, Inc. | -5.355M |
| ACADIA Pharmaceuticals, Inc. | 95.69M |
| Alnylam Pharmaceuticals, Inc. | 292.04M |